KFDA approves Exelon for treatment of dementia associated With Parkinson's disease

Published: 2006-09-15 06:56:00

Updated: 2006-09-15 06:56:00

Novartis Korea announced it has received from the Korea Food and Drug Administration an additional approval of Exelon (rivastigmine tartrate) for the treatment of mild to moderate dementia associated with Parkinson's disease.

The company said that Exelon is the first and only medication availa...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK